{"id":30842,"date":"2025-01-20T17:37:00","date_gmt":"2025-01-20T12:07:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30842"},"modified":"2025-02-07T09:49:54","modified_gmt":"2025-02-07T04:19:54","slug":"thyroid-eye-disease-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment","title":{"rendered":"Thyroid Eye Disease: The Hidden Impact of Thyroid Dysfunction on Eye Health"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a1a5ecdb755d\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a1a5ecdb755d\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\/#TEPEZZA_%E2%80%94_Only_Approved_Drug_for_Thyroid_Eye_Disease_Treatment\" >TEPEZZA \u2014 Only Approved Drug for Thyroid Eye Disease Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\/#Promising_Thyroid_Eye_Disease_Drugs_in_Line_for_Approval\" >Promising Thyroid Eye Disease Drugs in Line for Approval&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\/#Does_Slings_Oral_Linsitinib_a_Potential_Contender_to_Amgens_Intravenous_TEPEZZA\" >Does Sling\u2019s Oral Linsitinib a Potential Contender to Amgen\u2019s Intravenous TEPEZZA?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\/#Recent_Developments_in_the_Graves_Disease_Treatment_Space\" >Recent Developments in the Graves\u2019 Disease Treatment Space<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\/#Thyroid_Eye_Disease_Treatment_The_Road_Ahead\" >Thyroid Eye Disease Treatment: The Road Ahead<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Thyroid eye disease is a rare but serious autoimmune condition that affects the eyes, often linked to hyperthyroidism or Graves\u2019 disease. Around <strong>25-50%<\/strong> of people with Graves\u2019 disease develop TED, with women being more commonly affected than men.&nbsp;<\/p>\n\n\n\n<p>There were <strong>1.4 million<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/thyroid-eye-disease-ted-epidemiology-forecast\">diagnosed prevalent cases of TED<\/a> in 2023, with the number projected to rise by 2034, as per DelveInsight\u2019s Thyroid Eye Disease Epidemiology Forecast Report. In the 7MM, the US had the highest number of diagnosed prevalent cases of TED<\/p>\n\n\n\n<p>In 2023, the US reported the maximum number of mild cases, followed by moderate to severe cases, and sight-threatening cases of TED. These numbers are expected to rise during the forecast period from 2024 to 2034. The higher prevalence of early-stage cases across all forms of TED can be attributed to improved awareness, earlier detection, and better diagnostic tools. Additionally, efforts to reduce the stigma surrounding the condition have led to increased reporting of cases at all levels of severity.<\/p>\n\n\n\n<p>TED can significantly impact a person\u2019s quality of life, causing symptoms like dryness, redness, pain, and even vision problems. Early diagnosis and treatment are crucial to managing the disease and preventing long-term damage, emphasizing the need for greater awareness and research in this area.<\/p>\n\n\n\n<p><strong><em>Read our blog on <a href=\"https:\/\/www.delveinsight.com\/blog\/graves-disease-treatment-revolution\" class=\"ek-link\">Graves\u2019 Disease Treatment<\/a> to understand the difference between thyroid eye disease and Graves\u2019 disease<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-tepezza-only-approved-drug-for-thyroid-eye-disease-treatment\"><span class=\"ez-toc-section\" id=\"TEPEZZA_%E2%80%94_Only_Approved_Drug_for_Thyroid_Eye_Disease_Treatment\"><\/span><strong>TEPEZZA \u2014 Only Approved Drug for Thyroid Eye Disease Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Teprotumumab <\/strong>is a fully human <strong>IgG1 monoclonal antibody<\/strong> that inhibits the <strong>insulin-like Growth Factor-1 receptor (IGF-1R)<\/strong>. It is produced in Chinese hamster ovary (CHO-DG44) cells and has a molecular weight of approximately 148 kDa.<\/p>\n\n\n\n<p>In January 2020, the US FDA granted accelerated<strong> Priority Review<\/strong> approval for <strong>TEPEZZA <\/strong>as a treatment for thyroid eye disease. More recently, in September 2024, Japan\u2019s Ministry of Health, Labour, and Welfare (MHLW) approved the <a href=\"https:\/\/www.delveinsight.com\/report-store\/graves-orbitopathy-market\">drug for treating active Graves\u2019 orbitopathy<\/a>. Furthermore, in April 2024, Amgen announced its intent to submit a Marketing Authorization Application (MAA) for teprotumumab to the European Medicines Agency (EMA) in the near future.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"397\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1024x397.jpg\" alt=\"TEPEZZA-Developmental-Timeline\" class=\"wp-image-28915\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1024x397.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-300x116.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-150x58.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-768x298.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1536x596.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline-1568x609.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29162000\/TEPEZZA-Developmental-Timeline.jpg 1734w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Currently, TEPEZZA is being evaluated in Phase III clinical trials for moderate-to-severe active Graves\u2019 orbitopathy and chronic TED with a low Clinical Activity Score (CAS). Amgen is also investigating the feasibility of subcutaneous administration of the drug.<\/p>\n\n\n\n<p>However, with only one drug currently approved in the thyroid eye disease arena, there is a significant opportunity for companies to enter the thyroid eye disease treatment market.<\/p>\n\n\n\n<p><strong><em>Understand more about the evolving landscape of Graves\u2019 Ophthalmopathy by reading our article on <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/graves-ophthalmopathy-treatment\"><strong><em>Graves\u2019 Ophthalmopathy Treatment<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promising-thyroid-eye-disease-drugs-in-line-for-approval-nbsp\"><span class=\"ez-toc-section\" id=\"Promising_Thyroid_Eye_Disease_Drugs_in_Line_for_Approval\"><\/span><strong>Promising Thyroid Eye Disease Drugs in Line for Approval&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/thyroid-eye-disease-pipeline-insight\">thyroid eye disease treatment pipeline<\/a> is robust. Various potential therapies that are projected to enter the market during the forecast period include <strong>Viridian Therapeutics\u2019 VRDN-001(veligrotug), Argenx\u2019 Efgartigimod PH20 SC, Hoffmann-La Roche\u2019 ENSPRYNG (satralizumab, RG6168), Sling Therapeutics\u2019 Linsitinib, Tourmaline Bio\u2019 Pacibekitug (TOUR006), Lassen Therapeutics\u2019 LASN01, ACELYRIN\u2019 Lonigutamab, and Immunovant, Samsung Biologics, HanAll Biopharma and Roivant Sciences\u2019 IMVT-1401 (batoclimab, RVT-1401)<\/strong>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"566\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-1024x566.jpg\" alt=\"Emerging-Drugs-for-Thyroid-Eye-Disease\" class=\"wp-image-30843\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-1024x566.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-300x166.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-150x83.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-768x424.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-1536x849.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152648\/Emerging-Drugs-for-Thyroid-Eye-Disease-2048x1132.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The anticipated launch of these therapies from different pharmaceutical companies are set to compete with Amgen\u2019s market-leader TEPEZZA in the treatment of thyroid eye disease. These innovative treatments utilize advanced approaches, including targeted biologics and novel small molecules, which could provide benefits in terms of effectiveness, safety, and patient convenience. For example, certain emerging therapies for thyroid eye disease target specific inflammatory pathways or employ cutting-edge delivery systems to enhance therapeutic results.<\/p>\n\n\n\n<p><strong><em>Get detailed insights into the late-stage TED drugs at \u201c<\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/blog\/4-late-stage-thyroid-eye-disease-treatments\"><strong><em>Late-Stage Thyroid Eye Disease Treatments: 4 Prominent Therapies to Consider<\/em><\/strong><\/a><strong><em>\u201d<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-does-sling-s-oral-linsitinib-a-potential-contender-to-amgen-s-intravenous-tepezza\"><span class=\"ez-toc-section\" id=\"Does_Slings_Oral_Linsitinib_a_Potential_Contender_to_Amgens_Intravenous_TEPEZZA\"><\/span><strong>Does Sling\u2019s Oral Linsitinib a Potential Contender to Amgen\u2019s Intravenous TEPEZZA?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Recently in January 2025, <strong>Sling Therapeutics\u2019<\/strong> oral alternative to <strong>Amgen\u2019s intravenous TEPEZZA<\/strong> has shown positive results in a phase IIb\/III <a href=\"https:\/\/www.delveinsight.com\/report-store\/thyroid-eye-disease-market\">clinical trial for thyroid eye disease<\/a>, positioning the company to conduct a confirmatory study of its ex-Astellas asset. However, a comparison across trials indicates that Amgen\u2019s widely successful drug may have an edge in terms of efficacy.<\/p>\n\n\n\n<p>Astellas previously investigated the small-molecule IGF-1R inhibitor linsitinib as a cancer treatment. With TEPEZZA, an anti-IGF-1R antibody, demonstrating positive effects in TED, Sling saw an opportunity to explore linsitinib for the condition. The company began its efforts in 2022, securing <strong>$35 million<\/strong> to run a phase IIb trial in TED, a complication of Graves\u2019 disease that leads to eye bulging.<\/p>\n\n\n\n<p>About 18 months later, Sling has gathered evidence supporting linsitinib\u2019s efficacy in TED. In the trial, 90 patients were randomized to receive either one of two doses of linsitinib or a placebo. After 24 weeks, 52% of those on the higher dose showed a significant reduction in eye bulging, meeting the response criteria.&nbsp;<\/p>\n\n\n\n<p>The high dose response rate was notably higher than the placebo group, allowing it to meet the primary endpoint. Sling did not provide information on the performance of the lower dose and is now preparing to initiate a confirmatory phase III trial later this year.<\/p>\n\n\n\n<p>Safety and tolerability could be another key factor. The upcoming phase III trial will provide further insights into the molecule\u2019s safety and efficacy, potentially positioning Sling to compete with Amgen in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/thyroid-eye-disease-market\">TED market<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-recent-developments-in-the-graves-disease-treatment-space\"><span class=\"ez-toc-section\" id=\"Recent_Developments_in_the_Graves_Disease_Treatment_Space\"><\/span><strong>Recent Developments in the Graves\u2019 Disease Treatment Space<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>January 2025, Sling Therapeutics<\/strong> announced promising Phase IIb\/III results for linsitinib in treating thyroid eye disease, potentially paving the way for the first oral option to Amgen\u2019s intravenous TEPEZZA in a market that analysts believe is still largely untapped.<\/li>\n\n\n\n<li>In <strong>August 2024, ACELYRIN<\/strong> decided to pivot its focus from <strong>izokibep<\/strong>, despite the drug&#8217;s continued strong performance in clinical trials. The company laid off around 40 employees\u2014approximately 33% of its 135-person workforce\u2014to prioritize the development of lonigutamab, a potential competitor to Amgen\u2019s blockbuster drug, TEPEZZA.<\/li>\n\n\n\n<li>According to <strong>Immunovant\u2019s Q3 2024 annual report<\/strong> released in November, the company expects data from batoclimab trials in TED to be available in the second half of 2025. Additionally, a June 2024 SEC filing revealed that, following a recent Type B meeting with the US FDA, the company plans to launch four to five potentially registrational programs for IMVT-1402 across various therapeutic areas, including endocrinology and neurology, by March 2025.<\/li>\n\n\n\n<li><strong>Viridian Therapeutics<\/strong> aims to submit a Biologics License Application (BLA) for <strong>veligrotug <\/strong>in TED treatment by the second half of 2025. The company also expects topline data from the <strong>REVEAL-1 and REVEAL-2 trials of VRDN-003<\/strong>, targeting active and chronic TED, in the first half of 2026.<\/li>\n\n\n\n<li>In <strong>August 2023, Tourmaline Bio<\/strong> announced that the US FDA had approved its IND application for <strong>TOUR006<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-thyroid-eye-disease-treatment-the-road-ahead\"><span class=\"ez-toc-section\" id=\"Thyroid_Eye_Disease_Treatment_The_Road_Ahead\"><\/span><strong>Thyroid Eye Disease Treatment: The Road Ahead<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the coming years, the US thyroid eye disease market is set for significant change and growth, largely driven by the dominance of the already approved product, TEPEZZA. Additionally, we expect the launch of a second product, batoclimab, in the US within the next 2\u20133 years. Since only about 20% of thyroid eye disease cases are acute and treated, we anticipate market expansion, particularly with the introduction of safer and more effective therapies.&nbsp;<\/p>\n\n\n\n<p>Currently, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/thyroid-eye-disease-market\">market size of TED<\/a> in the 7MM was <strong>USD 2.3 billion<\/strong> in 2023, which is further expected to increase by 2034, as per DelveInsight\u2019s Thyroid Eye Disease Market Forecast Report. This growth is mainly driven by increasing awareness about TED may increase market size in the coming years, assisted by an increase in the prevalence of TED.&nbsp;<\/p>\n\n\n\n<p>Additionally, the arrival of new treatments, along with improved early patient screening, the integration of medications in secondary care settings, ongoing research on best implementation practices, and increased awareness, will contribute to the development of more effective treatment options. However, challenges remain in the timely diagnosis and treatment of patients, especially as the condition is classified as a rare disease. This rarity leads companies to set premium prices, which can be a barrier to the adoption of new therapies.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/thyroid-eye-disease-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-1024x194.png\" alt=\"Thyroid-Eye-Disease-Market-Outlook\" class=\"wp-image-28914\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook-1568x297.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/07\/29161929\/Thyroid-Eye-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Thyroid eye disease is a rare but serious autoimmune condition that affects the eyes, often linked to hyperthyroidism or Graves\u2019 disease. Around 25-50% of people with Graves\u2019 disease develop TED, with women being more commonly affected than men.&nbsp; There were 1.4 million diagnosed prevalent cases of TED in 2023, with the number projected to rise [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30845,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[17971,7777,7813,7780,7779,17976],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-30842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-tepezza","tag-thyroid-eye-disease","tag-thyroid-eye-disease-epidemiology","tag-thyroid-eye-disease-market","tag-thyroid-eye-disease-treatment","tag-thyroid-eye-disease-treatment-market","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Thyroid Eye Disease Treatment: What&#039;s on the Horizon?<\/title>\n<meta name=\"description\" content=\"Thyroid eye disease treatment pipeline is robust. Various potential therapies are projected to enter the market during the forecast period.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Thyroid Eye Disease Treatment: What&#039;s on the Horizon?\" \/>\n<meta property=\"og:description\" content=\"Thyroid eye disease treatment pipeline is robust. Various potential therapies are projected to enter the market during the forecast period.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-20T12:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-07T04:19:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152850\/thyroid-eye-disease-treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Thyroid Eye Disease Treatment: What's on the Horizon?","description":"Thyroid eye disease treatment pipeline is robust. Various potential therapies are projected to enter the market during the forecast period.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment","og_locale":"en_US","og_type":"article","og_title":"Thyroid Eye Disease Treatment: What's on the Horizon?","og_description":"Thyroid eye disease treatment pipeline is robust. Various potential therapies are projected to enter the market during the forecast period.","og_url":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-01-20T12:07:00+00:00","article_modified_time":"2025-02-07T04:19:54+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152850\/thyroid-eye-disease-treatment.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment","url":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment","name":"Thyroid Eye Disease Treatment: What's on the Horizon?","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152850\/thyroid-eye-disease-treatment.png","datePublished":"2025-01-20T12:07:00+00:00","dateModified":"2025-02-07T04:19:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Thyroid eye disease treatment pipeline is robust. Various potential therapies are projected to enter the market during the forecast period.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/thyroid-eye-disease-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152850\/thyroid-eye-disease-treatment.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152850\/thyroid-eye-disease-treatment.png","width":466,"height":284,"caption":"thyroid-eye-disease-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/01\/20152850\/thyroid-eye-disease-treatment-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Tepezza<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Thyroid eye disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Thyroid eye disease epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Thyroid eye disease market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Thyroid eye disease treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Thyroid Eye Disease Treatment Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Tepezza<\/span>","<span class=\"advgb-post-tax-term\">Thyroid eye disease<\/span>","<span class=\"advgb-post-tax-term\">Thyroid eye disease epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Thyroid eye disease market<\/span>","<span class=\"advgb-post-tax-term\">Thyroid eye disease treatment<\/span>","<span class=\"advgb-post-tax-term\">Thyroid Eye Disease Treatment Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jan 20, 2025","modified":"Updated on Feb 7, 2025"},"absolute_dates_time":{"created":"Posted on Jan 20, 2025 5:37 pm","modified":"Updated on Feb 7, 2025 9:49 am"},"featured_img_caption":"thyroid-eye-disease-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30842"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30842\/revisions"}],"predecessor-version":[{"id":30847,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30842\/revisions\/30847"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30845"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30842"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30842"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}